Jounce Misses in Phase 2 Trial in Lung Cancer

 SELECT trial of vopratelimab in combination with pimivalimab versus pimivalimab alone did not meet its primary endpoint of mean tumor change averaged over 9 and 18 weeks -

- Encouraging trends in improved mean tumor change over 9 and 18 weeks, and secondary endpoints of overall response rate (ORR) and progression free survival (PFS) were observed in the low dose vopratelimab arm in combination with pimivalimab compared to pimivalimab alone -

- Pimivalimab monotherapy continues to demonstrate safety and clinical activity -

https://finance.yahoo.com/news/jounce-therapeutics-reports-results-phase-120000389.html